exoASO STAT6
Alternative Names: CDK 004; exoASO™-STAT6Latest Information Update: 13 Jun 2023
At a glance
- Originator Codiak BioSciences
- Class Antineoplastics; Antisense oligonucleotides; Exosome therapies; Immunotherapies
- Mechanism of Action RNA interference; STAT6 transcription factor inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase I Liver cancer; Liver metastases
- Preclinical Colorectal cancer; Glioma; Lung cancer; Ovarian cancer; Pancreatic cancer; Thyroid cancer; Uveal melanoma
Most Recent Events
- 30 May 2023 Codiak BioSciences terminates a phase I trial in Liver metastases and Liver cancer (Late-stage disease, Second-line therapy or greater) in USA (IV) due to Company bankruptcy (NCT05375604)
- 10 Nov 2022 Pharmacodynamics data from preclinical studies in Cancer released by Codiak BioSciences
- 16 May 2022 Phase-I clinical trials in Liver metastases (Late-stage disease, Second-line therapy or greater) in USA (IV) (NCT05375604)